Literature DB >> 21606503

Enhanced biosynthesis of coagulation factor VIII through diminished engagement of the unfolded protein response.

Harrison C Brown1, Bagirath Gangadharan, Christopher B Doering.   

Abstract

Human and porcine coagulation factor VIII (fVIII) display a biosynthetic efficiency differential that is being exploited for the development of new protein and gene transfer-based therapies for hemophilia A. The cellular and/or molecular mechanism(s) responsible for this phenomenon have yet to be uncovered, although it has been temporally localized to post-translational biosynthetic steps. The unfolded protein response (UPR) is a cellular adaptation to structurally distinct (e.g. misfolded) or excess protein in the endoplasmic reticulum and is known to be induced by heterologous expression of recombinant human fVIII. Therefore, it is plausible that the biosynthetic differential between human and porcine fVIII results from differential UPR activation. In the current study, UPR induction was examined in the context of ongoing fVIII expression. UPR activation was greater during human fVIII expression when compared with porcine fVIII expression as determined by ER response element (ERSE)-luciferase reporter activity, X-box-binding protein 1 (XBP1) splicing, and immunoglobulin-binding protein (BiP) up-regulation. Immunofluorescence microscopy of fVIII expressing cells revealed that human fVIII was notably absent in the Golgi apparatus, confirming that endoplasmic reticulum to Golgi transport is rate-limiting. In contrast, a significant proportion of porcine fVIII was localized to the Golgi indicating efficient transit through the secretory pathway. Overexpression of BiP, an integral UPR protein, reduced the secretion of human fVIII by 50%, but had no effect on porcine fVIII biosynthesis. In contrast, expression of BiP shRNA increased human fVIII expression levels. The current data support the model of differential engagement of UPR by human and porcine fVIII as a non-traditional mechanism for regulation of gene product biosynthesis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21606503      PMCID: PMC3129224          DOI: 10.1074/jbc.M111.238758

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  27 in total

Review 1.  Quality control in the endoplasmic reticulum.

Authors:  Lars Ellgaard; Ari Helenius
Journal:  Nat Rev Mol Cell Biol       Date:  2003-03       Impact factor: 94.444

2.  High level expression of recombinant porcine coagulation factor VIII.

Authors:  Christopher B Doering; John F Healey; Ernest T Parker; Rachel T Barrow; Pete Lollar
Journal:  J Biol Chem       Date:  2002-07-23       Impact factor: 5.157

Review 3.  Haemophilia A and von Willebrand's disease.

Authors:  A C Goodeve; S Rosén; B Verbruggen
Journal:  Haemophilia       Date:  2010-07       Impact factor: 4.287

4.  Prophylactic use of factor VIII: an economic evaluation.

Authors:  R L Bohn; J Avorn; R J Glynn; I Choodnovskiy; R Haschemeyer; L M Aledort
Journal:  Thromb Haemost       Date:  1998-05       Impact factor: 5.249

5.  Lentiviral vector platform for production of bioengineered recombinant coagulation factor VIII.

Authors:  H Trent Spencer; Gabriela Denning; Richard E Gautney; Boro Dropulic; Andre J Roy; Lajos Baranyi; Bagirath Gangadharan; Ernest T Parker; Pete Lollar; Christopher B Doering
Journal:  Mol Ther       Date:  2010-11-16       Impact factor: 11.454

Review 6.  Combined Factor V and Factor VIII Deficiency.

Authors:  Marta Spreafico; Flora Peyvandi
Journal:  Semin Thromb Hemost       Date:  2009-07-13       Impact factor: 4.180

Review 7.  The endoplasmic reticulum stress response in immunity and autoimmunity.

Authors:  Derrich J Todd; Ann-Hwee Lee; Laurie H Glimcher
Journal:  Nat Rev Immunol       Date:  2008-09       Impact factor: 53.106

8.  Antioxidants reduce endoplasmic reticulum stress and improve protein secretion.

Authors:  Jyoti D Malhotra; Hongzhi Miao; Kezhong Zhang; Anna Wolfson; Subramaniam Pennathur; Steven W Pipe; Randal J Kaufman
Journal:  Proc Natl Acad Sci U S A       Date:  2008-11-14       Impact factor: 11.205

9.  Directed engineering of a high-expression chimeric transgene as a strategy for gene therapy of hemophilia A.

Authors:  Christopher B Doering; Gabriela Denning; Kerry Dooriss; Bagirath Gangadharan; Jennifer M Johnston; Keith W Kerstann; David A McCarty; H Trent Spencer
Journal:  Mol Ther       Date:  2009-03-03       Impact factor: 11.454

10.  The relationship of N-linked glycosylation and heavy chain-binding protein association with the secretion of glycoproteins.

Authors:  A J Dorner; D G Bole; R J Kaufman
Journal:  J Cell Biol       Date:  1987-12       Impact factor: 10.539

View more
  27 in total

1.  Molecular coevolution of coagulation factor VIII and von Willebrand factor.

Authors:  Philip M Zakas; Christopher W Coyle; Anja Brehm; Marion Bayer; Barbara Solecka-Witulska; Caelan E Radford; Christine Brown; Kate Nesbitt; Courtney Dwyer; Christoph Kannicht; H Trent Spencer; Eric A Gaucher; Christopher B Doering; David Lillicrap
Journal:  Blood Adv       Date:  2021-02-09

2.  Engineered Hematopoietic Stem Cells as Therapeutics for Hemophilia A.

Authors:  Philip M Zakas; H Trent Spencer; Christopher B Doering
Journal:  J Genet Syndr Gene Ther       Date:  2011-11-16

3.  Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A.

Authors:  Lindsey A George; Paul E Monahan; M Elaine Eyster; Spencer K Sullivan; Margaret V Ragni; Stacy E Croteau; John E J Rasko; Michael Recht; Benjamin J Samelson-Jones; Amy MacDougall; Kristen Jaworski; Robert Noble; Marla Curran; Klaudia Kuranda; Federico Mingozzi; Tiffany Chang; Kathleen Z Reape; Xavier M Anguela; Katherine A High
Journal:  N Engl J Med       Date:  2021-11-18       Impact factor: 91.245

4.  Investigating Optimal Autologous Cellular Platforms for Prenatal or Perinatal Factor VIII Delivery to Treat Hemophilia A.

Authors:  Christopher Stem; Christopher Rodman; Ritu M Ramamurthy; Sunil George; Diane Meares; Andrew Farland; Anthony Atala; Christopher B Doering; H Trent Spencer; Christopher D Porada; Graça Almeida-Porada
Journal:  Front Cell Dev Biol       Date:  2021-08-10

5.  Chemical stresses fail to mimic the unfolded protein response resulting from luminal load with unfolded polypeptides.

Authors:  Timothy J Bergmann; Ilaria Fregno; Fiorenza Fumagalli; Andrea Rinaldi; Francesco Bertoni; Paul J Boersema; Paola Picotti; Maurizio Molinari
Journal:  J Biol Chem       Date:  2018-02-16       Impact factor: 5.157

6.  Preclinical Development of a Hematopoietic Stem and Progenitor Cell Bioengineered Factor VIII Lentiviral Vector Gene Therapy for Hemophilia A.

Authors:  Christopher B Doering; Gabriela Denning; Jordan E Shields; Eli J Fine; Ernest T Parker; Alok Srivastava; Pete Lollar; H Trent Spencer
Journal:  Hum Gene Ther       Date:  2018-10       Impact factor: 5.695

7.  The 3.2 Å structure of a bioengineered variant of blood coagulation factor VIII indicates two conformations of the C2 domain.

Authors:  Ian W Smith; Anne E d'Aquino; Christopher W Coyle; Andrew Fedanov; Ernest T Parker; Gabriela Denning; Harold Trent Spencer; Pete Lollar; Christopher B Doering; Paul Clint Spiegel
Journal:  J Thromb Haemost       Date:  2019-09-08       Impact factor: 5.824

8.  Mechanistic Insights into Factor VIII Immune Tolerance Induction via Prenatal Cell Therapy in Hemophilia A.

Authors:  Martin Rodriguez; Christopher D Porada; Graҫa Almeida-Porada
Journal:  Curr Stem Cell Rep       Date:  2019-11-20

Review 9.  Gene therapy for hemophilia.

Authors:  Geoffrey L Rogers; Roland W Herzog
Journal:  Front Biosci (Landmark Ed)       Date:  2015-01-01

10.  Non-genotoxic conditioning facilitates hematopoietic stem cell gene therapy for hemophilia A using bioengineered factor VIII.

Authors:  Athena L Russell; Chengyu Prince; Taran S Lundgren; Kristopher A Knight; Gabriela Denning; Jordan S Alexander; Jaquelyn T Zoine; H Trent Spencer; Shanmuganathan Chandrakasan; Christopher B Doering
Journal:  Mol Ther Methods Clin Dev       Date:  2021-05-05       Impact factor: 6.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.